Sotera Health Company (SHC) Financial Ratios
8 years of historical data (2018–2025) · Healthcare · Medical - Diagnostics & Research
EV/EBITDA
↑
21.09
↑+29% vs avg
5yr avg: 16.41
30Y Low10.1·High27.4
P/FCF
↓
29.95
↓-34% vs avg
5yr avg: 45.35
30Y Low24.4·High115.9
P/B Ratio
↓
7.41
↓-21% vs avg
5yr avg: 9.32
30Y Low6.7·High17.1
ROE
↓
15.4%
↓+576% vs avg
5yr avg: 2.3%
30Y Low-50%·High22%
Debt/EBITDA
↑
7.50
↑+36% vs avg
5yr avg: 5.52
30Y Low4.5·High9.8
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
SHC Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Sotera Health Company trades at 58.0x earnings, 23% below its 5-year average of 75.5x, sitting at the 25th percentile of its historical range. Compared to the Healthcare sector median P/E of 22.3x, the stock trades at a premium of 160%. On a free-cash-flow basis, the stock trades at 30.0x P/FCF, 34% below the 5-year average of 45.3x.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $4.5B | $5.1B | $3.9B | $4.8B | $2.3B | $6.6B | $7.8B | — | — |
| Enterprise Value | $6.4B | $7.0B | $6.0B | $6.8B | $4.0B | $8.3B | $9.6B | — | — |
| P/E Ratio → | 58.04 | 65.33 | 85.50 | 93.61 | — | 57.44 | — | — | — |
| P/S Ratio | 3.84 | 4.34 | 3.54 | 4.55 | 2.32 | 7.06 | 9.50 | — | — |
| P/B Ratio | 7.41 | 8.34 | 9.63 | 10.75 | 6.66 | 11.23 | 17.10 | — | — |
| P/FCF | 29.95 | 33.87 | 86.43 | — | 24.41 | 36.68 | 115.87 | — | — |
| P/OCF | 15.56 | 17.59 | 17.39 | — | 8.39 | 23.37 | 64.46 | — | — |
P/E links to full P/E history page with 30-year chart
SHC EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
Sotera Health Company's enterprise value stands at 21.1x EBITDA, 29% above its 5-year average of 16.4x. The Healthcare sector median is 14.4x, placing the stock at a 47% premium on an enterprise-value basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 6.00 | 5.43 | 6.48 | 3.96 | 8.91 | 11.71 | — | — |
| EV / EBITDA | 21.09 | 23.02 | 12.94 | 15.65 | 10.08 | 20.36 | 27.40 | — | — |
| EV / EBIT | 16.28 | 23.02 | 21.43 | 27.33 | — | 33.21 | 54.30 | — | — |
| EV / FCF | — | 46.79 | 132.41 | — | 41.53 | 46.27 | 142.81 | — | — |
SHC Profitability
Margins and return-on-capital ratios measuring operating efficiency
Sotera Health Company earns an operating margin of 33.8%. Operating margins have expanded from 26.4% to 33.8% over the past 3 years, signaling improving operational efficiency. ROE of 15.4% indicates solid capital efficiency. ROIC of 11.8% represents solid returns on invested capital.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 55.5% | 55.5% | 54.7% | 55.0% | 55.5% | 55.7% | 54.2% | 50.8% | 47.9% |
| Operating Margin | 33.8% | 33.8% | 27.0% | 26.4% | 24.7% | 27.6% | 25.2% | 23.6% | 10.8% |
| Net Profit Margin | 6.7% | 6.7% | 4.0% | 4.9% | -23.3% | 12.5% | -4.7% | -2.7% | -0.8% |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| ROE | 15.4% | 15.4% | 10.5% | 12.9% | -49.9% | 22.5% | -8.5% | — | -12.9% |
| ROA | 2.5% | 2.5% | 1.4% | 1.6% | -7.9% | 4.2% | -1.4% | -0.8% | -0.2% |
| ROIC | 11.8% | 11.8% | 9.0% | 9.3% | 8.7% | 8.4% | 7.0% | 6.4% | 2.8% |
| ROCE | 13.3% | 13.3% | 10.3% | 10.6% | 10.0% | 9.8% | 8.1% | 7.3% | 3.2% |
SHC Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
Sotera Health Company carries a Debt/EBITDA ratio of 7.5x, which is highly leveraged (128% above the sector average of 3.3x). Net debt stands at $1.9B ($2.3B total debt minus $346M cash). Interest coverage of just 1.9x is concerning — the company has limited headroom to absorb earnings volatility before struggling with debt service.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 3.75 | 3.75 | 5.81 | 5.24 | 5.80 | 3.12 | 4.20 | — | 49.19 |
| Debt / EBITDA | 7.50 | 7.50 | 5.10 | 5.35 | 5.16 | 4.48 | 5.46 | 8.62 | 9.83 |
| Net Debt / Equity | — | 3.18 | 5.12 | 4.58 | 4.67 | 2.94 | 3.97 | — | 47.08 |
| Net Debt / EBITDA | 6.36 | 6.36 | 4.50 | 4.67 | 4.16 | 4.22 | 5.17 | 8.43 | 9.41 |
| Debt / FCF | — | 12.92 | 45.98 | — | 17.12 | 9.59 | 26.94 | 30.35 | 45.61 |
| Interest Coverage | 1.95 | 1.95 | 1.69 | 1.74 | -2.03 | 3.37 | 0.82 | 0.99 | 1.17 |
SHC Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Sotera Health Company's current ratio of 2.46x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.46 | 2.46 | 2.75 | 2.42 | 0.81 | 2.15 | 2.24 | 2.04 | 2.18 |
| Quick Ratio | 2.24 | 2.24 | 2.50 | 2.21 | 0.77 | 1.81 | 2.00 | 1.73 | 1.92 |
| Cash Ratio | 1.39 | 1.39 | 1.45 | 1.29 | 0.50 | 0.66 | 0.73 | 0.51 | 0.67 |
| Asset Turnover | — | 0.36 | 0.36 | 0.34 | 0.32 | 0.33 | 0.30 | 0.30 | 0.28 |
| Inventory Turnover | 9.53 | 9.53 | 10.13 | 9.77 | 12.03 | 7.60 | 10.99 | 10.24 | 10.34 |
| Days Sales Outstanding | — | 55.29 | 55.00 | 61.06 | 56.63 | 52.53 | 58.45 | 52.33 | 69.27 |
SHC Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Sotera Health Company does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business. The earnings yield of 1.7% (inverse of P/E) provides a useful comparison to bond yields when assessing the stock's relative attractiveness to fixed income.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | 1.7% | 1.5% | 1.2% | 1.1% | — | 1.7% | — | — | — |
| FCF Yield | 3.3% | 3.0% | 1.2% | — | 4.1% | 2.7% | 0.9% | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.1% | 0.1% | 0.0% | 0.0% | 0.4% | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.1% | 0.1% | 0.0% | 0.0% | 0.4% | — | — |
| Shares Outstanding | — | $286M | $285M | $283M | $280M | $279M | $283M | $284M | $246M |
Peer Comparison
Compare SHC with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 SHCYou | $4B | 58.0 | 21.1 | 30.0 | 55.5% | 33.8% | 15.4% | 11.8% | 7.5 |
 STRL | $25B | 86.5 | 50.6 | 68.6 | 22.1% | 16.6% | 30.0% | 38.9% | 0.7 |
 ICLR | $10B | 13.1 | 7.9 | 8.5 | 29.4% | 13.3% | 8.4% | 6.5% | 2.3 |
 CRL | $9B | -62.5 | 13.0 | 17.3 | 30.5% | 12.6% | -4.3% | 6.3% | 3.4 |
 MEDP | $12B | 28.1 | 21.3 | 18.0 | 30.1% | 21.1% | 70.2% | 154.9% | 0.4 |
 PINC | $2B | 128.5 | 21.3 | 7.3 | 73.4% | 0.1% | 1.2% | 0.0% | 2.4 |
 BCO | $4B | 22.9 | 8.0 | 10.2 | 25.8% | 11.3% | 55.5% | 14.3% | 5.6 |
 BRKR | $7B | -291.5 | 18.4 | 153.7 | 45.9% | 6.9% | -0.4% | 4.4% | 4.5 |
 NEOG | $2B | -1.8 | 20.7 | — | 47.1% | 1.1% | -41.9% | 0.2% | 6.8 |
 BAX | $9B | -10.0 | 25.4 | 28.0 | 30.1% | -2.7% | -14.6% | -1.4% | 14.9 |
 BDX | $56B | 26.3 | 14.7 | 20.8 | 45.4% | 11.8% | 6.5% | 4.3% | 3.8 |
| Healthcare Median | — | 22.3 | 14.4 | 18.5 | 63.9% | -5.2% | -33.7% | -11.2% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 8 years · Updated daily
See SHC's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs SHC Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare SHC vs STRL
Side-by-side business, growth, and profitability comparison vs Sterling Infrastructure, Inc..
Start ComparisonSHC — Frequently Asked Questions
Quick answers to the most common questions about buying SHC stock.
What is Sotera Health Company's P/E ratio?
Sotera Health Company's current P/E ratio is 58.0x. The historical average is 75.5x. This places it at the 25th percentile of its historical range.
What is Sotera Health Company's EV/EBITDA?
Sotera Health Company's current EV/EBITDA is 21.1x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 18.2x.
What is Sotera Health Company's ROE?
Sotera Health Company's return on equity (ROE) is 15.4%. The historical average is -1.4%.
Is SHC stock overvalued?
Based on historical data, Sotera Health Company is trading at a P/E of 58.0x. This is at the 25th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
What are Sotera Health Company's profit margins?
Sotera Health Company has 55.5% gross margin and 33.8% operating margin. Operating margin above 20% indicates strong pricing power and cost efficiency.
How much debt does Sotera Health Company have?
Sotera Health Company's Debt/EBITDA ratio is 7.5x, indicating high leverage. A ratio above 4x may signal elevated financial risk.